Please assess the completion status of the following clinical trial:

Trial Title: VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Type 2 Diabetes Mellitus (T2DM) diagnosed ≤ 24 months ago~* glycosylated hemoglobin (HbA1c) ≥6.5% and ≤7.5% at Visit 1~* Treatment-naïve.~* Body mass index (BMI) ≥22 and ≤40 kg/m2 at Visit 1~Key Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Fasting plasma glucose (FPG) ≥ 270 mg/dL (≥ 15.0 mmol/L)~* Previous or current participation in any vildagliptin clinical study.~* History of hypersensitivity to dipeptidyl peptidase-4 (DPP-4) inhibitors.~* Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.~* Donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Vilda 50mg bid + metformin (Type: ACTIVE_COMPARATOR): Metformin + vildagliptin
- Placebo + metformin (Type: EXPERIMENTAL): Metformin + Placebo of vildagliptin

Based on this trial design, predict the completion outcome and termination type (if applicable).